(Circulation. 1999;99:271-275.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Endothelin-1 and Blood Pressure After Inhibition of Nitric Oxide Synthesis in Human Septic Shock
From the Departments of Surgery (J.A.M.A., H.A.B.) and Internal Medicine (F.B., A.v.d.M., F.H.d.J.), University Hospital Rotterdam, Netherlands.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—The systemic hypotension during human sepsis has been ascribed to increased production of nitric oxide (NO). Therefore, inhibitors of NO synthesis have been used in the treatment of hypotension in patients with septic shock. In addition, NO production may inhibit the synthesis and vasoconstrictor effects of endothelin-1 (ET-1). In this study, we tested whether ET-1 contributed to the vasopressor action of the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) in patients with severe septic shock.
Methods and Results—Compared with healthy volunteers, patients with septic shock had increased plasma levels of nitrite/nitrate (37±5 [SEM] versus 12±5 mmol/L, P<0.01), the stable end products of NO metabolism, and ET-1 (45±7 versus 3±2 pg/mL, P<0.001). Plasma ET-1 concentration was not related to plasma nitrite/nitrate concentration or blood pressure. Continuous infusion of L-NAME (1 mg · kg-1 · h-1 IV) for 12 hours increased mean arterial pressure by 43±5% and systemic vascular resistance by 64±10% (both P<0.01). The increase in blood pressure and systemic vascular resistance correlated positively with the level of ET-1 (both P<0.005) but not with plasma nitrite/nitrate level. L-NAME infusion did not result in significant changes in the plasma concentrations of ET-1 or nitrite/nitrate.
Conclusions—NO and ET-1 may both play a role in the cardiovascular derangements of human sepsis. Although L-NAME does not increase ET-1 concentration in patients with septic shock, the vasopressor response induced by L-NAME depends on the plasma level of ET-1. These findings may indicate that inhibitors of NO synthesis unmask a tonic pressor response of ET-1 in human septic shock.
Key Words: endothelium-derived factors • shock • endothelin
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Recent evidence suggests a complex interaction of endothelium-derived factors, including endothelin-1 (ET-1) and nitric oxide (NO), in the control of vascular smooth muscle tone in health and disease.1 ET-1 is a 21-amino-acid peptide with potent vasoconstrictor actions in animals and humans.2 3 NO is a short-lived radical, derived from the amino acid L-arginine by the enzyme NO synthase, with direct vasodilatory action.4 5 In vitro experiments show that continuous NO production inhibits the synthesis6 and vasoconstrictor action of ET-1.7 Furthermore, endothelin receptor antagonists fail to affect blood pressure in normal animals.8 This apparent absence of vascular effects of ET-1 has been attributed to continuous NO production. This is further supported by the finding that inhibition of NO synthesis in rats can unmask a tonic pressor response of endothelin and results in increased plasma levels of ET-1.9 10 So far, the precise interaction of ET-1 and NO in humans remains to be determined.11 12
Sepsis in humans is characterized by massive vasodilatation with low systemic vascular resistance, high cardiac output, and severe hypotension.13 Increased production of NO by an inducible isotype of NO synthase has been held responsible for the cardiovascular derangements during sepsis.5 14 High levels of nitrite and nitrate, the stable end products of NO metabolism, are found in patients with severe sepsis, and these levels may correlate with vasodilation.15 Analogues of L-arginine competitively inhibit the production of NO from L-arginine16 and can reverse hypotension in endotoxin- and cytokine-induced shock in animals.5 17 More recently, these inhibitors of NO synthesis have been used to increase blood pressure in sepsis in humans.18 19 20 At present, it is unknown whether inhibition of NO synthesis modulates endothelin release in septic shock. Because high levels of endothelin-1 have been found in patients with septic shock,21 22 we hypothesized that part of the vasoconstrictive response after inhibition of NO synthesis may result from increased production of ET-1.
The purpose of the present study was to examine whether ET-1 plays a role in the increase in blood pressure after inhibition of NO synthesis in patients with severe sepsis. Plasma concentrations of ET-1 and nitrite/nitrate, as an indirect measure of NO production, were measured during continuous infusion of the L-arginine analogue NG-nitro-L-arginine methyl ester (L-NAME) in patients with severe septic shock.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
Our hospital Medical and Ethics Committee approved the study. First-degree relatives were informed of the nature of the study and gave informed consent. Eleven adult, critically ill patients in the intensive care unit of our hospital were included in the study. All patients met the criteria of sepsis as described by Bone et al.23 The source for sepsis was peritonitis (n=5), pneumonia (n=2), pancreatitis (n=2), mediastinitis (n=1), or peritonitis with pneumonia (n=1). Patients were in shock (systolic blood pressure <90 mm Hg or a decrease >40 mm Hg from baseline unresponsive to fluid challenge) on admission, requiring therapy with pressor agents. At the time of the study, all patients were receiving dopamine >15 mg · kg-1 · min-1 and/or norepinephrine >0.1 mg · kg-1 · min-1. All patients required mechanical ventilation because of respiratory failure. Four patients required continuous hemodialysis because of renal failure. Only patients with cardiac index >3.0 L · min-1 · m-2 were included, because earlier reports have shown reductions of cardiac output during inhibition of NO synthesis. Exclusion criteria for the study were severe coronary artery stenosis (angina pectoris grade III according to NYHA classification), pregnancy, and cardiac index <3.0 L · min-1 · m-2.
Study Protocol
All patients underwent continuous ECG monitoring and had
indwelling radial artery and pulmonary artery catheters
(Criticath, Ohmeda). Measurements of systemic arterial
blood pressure, central venous pressure, pulmonary artery
pressure, and cardiac output (thermodilution method) were made at
baseline and at 0.5-, 1-, 3-, and 6-hour intervals, for a total period
of 24 hours. Systemic and pulmonary vascular resistance were
calculated according to standard formulas. After baseline measurements,
infusion of L-NAME 1 mg · kg-1 ·
h-1 was started and continued for 12 hours. To
minimize the potential of developing toxicity from high serum levels of
L-NAME, infusion was not continued for longer periods. Maximum changes
in blood pressure and systemic vascular resistance were noted after 30
minutes of L-NAME administration,20 and
hemodynamic variables at this time were used to
compare with the baseline value. Concomitant therapy was at the
discretion of the clinician managing the patient.
Blood Samples
For later determination of plasma ET-1, nitrite/nitrate, and
cortisol, arterial blood samples (10 mL) were obtained in
heparin-coated blood collection tubes (Vacutainer) at baseline (t=0),
during L-NAME infusion (t=0.5, 1, 3, 6, and 12 hours), and 3, 6, and 12
hours after L-NAME infusion had stopped (t=15, 18, and 24 hours).
Control values were established in 10 healthy volunteers. Blood samples
were immediately centrifuged (1500g, 10 minutes,
4°C), and plasma was collected and stored at -80°C until tested.
Creatinine concentration was determined by a standard
method.
Determination of ET-1
ET-1 was determined, after Sep-Pak extraction, with a
commercially available radioimmunoassay kit (Nichols Institute) as
previously described.24 Normal values in our laboratory
were 1 to 5 pg/mL. The limit of detection was 1 pg/mL.
Determination of Nitrite/Nitrate Concentration
Total nitrite plus nitrate concentration was assayed as
described by Phizackerley and Al-Dabbagh.25 To reduce
nitrate to nitrite, supernatant or standards were incubated at room
temperature in the presence of Klebsiella pneumoniae under
anaerobic conditions. Total nitrite in the supernatant was
subjected to the Griess reaction and assayed spectrophotometrically.
Data are reported as the sum of nitrite plus nitrate. Normal values in
our laboratory were 5 to 15 mmol/L. The limit of detection was
0.1 mmol/L.
Determination of Cortisol
Cortisol concentrations were determined with a commercially
available radioimmunoassay kit (DPC) as described
previously.26 Normal values were 400 to 800 nmol/L (15 to
30 mg/dL). The limit of detection was 28 nmol/L.
Drugs
L-NAME was obtained from Sigma Chemical Co. The hospital
pharmacy prepared a sterile and pyrogen-free solution of L-NAME 10
mg/mL, ready for intravenous infusion.
Data Analysis
All results are expressed as mean±SEM. Changes over time were
compared with baseline values by repeated-measures ANOVA. Differences
between groups were compared by Student's t test. Pearson
correlation and scatterplots were used for analysis of
correlation between variables. A value of P<0.05 was
considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patient characteristics are shown in the Table
. All patients had
hypotension, low systemic vascular resistance, high cardiac output, and
increased serum creatinine due to septic shock
(Table). Compared with healthy volunteers, plasma levels of
ET-1, nitrate/nitrate, and cortisol were significantly increased (all
P<0.05, Table). Mortality at 28 days was 55%.
|
No correlation was found between plasma ET-1 concentration and plasma
nitrite/nitrate concentration (r=0.07, P>0.80),
blood pressure (r=-0.34, P=0.30), systemic
vascular resistance (r=-0.41, P=0.22), or
creatinine concentration (r=-0.13,
P=0.69). ET-1 concentration was 46±5 pg/mL in survivors and
43±12 pg/mL in nonsurvivors (P>0.05). Plasma
nitrite/nitrate concentration was negatively correlated with systemic
vascular resistance (r=-0.78, P=0.012) (Figure 1) but not with creatinine
concentration (r=-0.03, P=0.93).
|
Continuous infusion of L-NAME 1 mg ·
kg-1 · h-1 IV
resulted in a maximum increase of mean arterial pressure by
43±5% and systemic vascular resistance by 64±10% (Figure 2). There was a concomitant reduction in
cardiac output by 20±4%. The increase in blood pressure
(r=0.84, P=0.001) and systemic vascular
resistance (r=0.81, P=0.002) during L-NAME
infusion correlated positively with the baseline plasma concentration
of ET-1 (Figure 3). The increase in blood
pressure with L-NAME did not correlate with plasma nitrite/nitrate
level (r=0.12, P=0.89). L-NAME infusion for a
period of 12 hours did not result in changes in the plasma
concentration levels of ET-1 (from 45±7 pg/mL at baseline to 43±6
pg/mL after 12 hours of L-NAME, P>0.05) and/or cortisol
(from 753±86 nmol/L at baseline to 682±73 nmol/L after 12 hours of
L-NAME, P>0.05; Figure 4).
Plasma nitrite/nitrate did not change during L-NAME (from 37±5
mmol/L at baseline to 36±5 mmol/L after 12 hours of L-NAME,
P>0.05).
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Inhibitors of NO synthase have recently been presented as new therapeutic tools in the management of hypotension in septic shock in humans.18 19 20 The present study demonstrates that the increases in blood pressure and the magnitude of the vasopressor response induced by the NO synthase inhibitor L-NAME are related to the plasma level of ET-1. These findings may suggest that inhibitors of NO synthesis unmask a tonic pressor response of ET-1 in human septic shock. In addition, this study shows that prolonged inhibition of NO synthesis with L-NAME does not further increase the already elevated plasma ET-1 concentration.
In the present study, elevated plasma levels of ET-1 were found in patients with severe sepsis, as has been reported by others.21 22 The mechanism involved in the increase of ET-1 concentration during sepsis is largely unknown. High ET-1 levels could have resulted from increased synthesis and/or diminished clearance of ET-1. Levels of circulating cytokines, such as tumor necrosis factor and interleukins, are increased in septic shock and may stimulate ET-1 production in endothelial cells and macrophages.27 28 Furthermore, intravascular leakage of ET-1 from damaged endothelial cells may have occurred.13 Because most patients with septic shock had impaired renal function, diminished renal clearance could have played a role.29 30 However, no correlation was found between plasma ET-1 and creatinine in the present study. This supports the idea that increased generation of endothelin occurs in sepsis in humans, although other vascular beds, including liver and skeletal muscles, may also contribute to the clearance of ET-1.
The finding that high ET-1 levels coincided with high nitrite/nitrate
levels as an indirect measure of increased NO production is not
in line with previous data that indicate an inhibitory
action of NO on ET-1 release.1 6 This suggests that the
normal interaction between NO and ET-1 is disturbed during sepsis.
Abnormalities in the balance between vasoconstricting and vasodilating
factors have been reported during sepsis.13 31 At
present, however, the exact interaction of ET-1 and NO in septic
shock remains to be determined. We hypothesize that the high
circulating ET-1 concentration helps to maintain vascular tone during
sepsis and opposes the vascular smooth muscle relaxation induced by
increased NO production. Indeed, the high circulating ET-1
levels in patients with septic shock, in the present study 45 pg/mL
(
18 pmol/L), are sufficient to induce relevant
vasoconstriction.32 33 The fact that the increase in blood
pressure with L-NAME correlated with the level of ET-1 further supports
the idea of a continuous vasopressor tone by ET-1 during sepsis in
humans and that this vasopressor tone is unmasked by an
inhibitor of NO synthesis. Our findings are
consistent with previous reports in normal rats in which the
increase in blood pressure with L-NAME was reduced with the specific
endothelin receptor antagonist bosentan.9 10
In healthy humans34 and humans with chronic heart
failure,35 endothelin receptor antagonists can
reduce blood pressure. To demonstrate a direct relation between ET-1
and blood pressure, however, the use of a receptor blocker specific for
ET-1 would be necessary. In the present study, we did not test the
effects of an endothelin receptor antagonist. We
hypothesize that endothelin receptor antagonism during septic shock in
humans, in which plasma levels of ET-1 are high, would be detrimental,
because it may result in severe hypotension. Whether endothelin
receptor antagonists can prevent the increase in blood
pressure of NO synthase inhibitors in humans remains to be
determined.
In the present study, no increase was found in the plasma levels of ET-1 during 12 hours of inhibition of NO synthesis with L-NAME. These findings may suggest that ET-1 release itself is not modulated by L-NAME in patients with septic shock. In normal rats, acute inhibition of NO synthesis results in modest increases in ET-1 levels, but these ET-1 levels were measured only 15 and 35 minutes after L-NAME infusion.9 10 In contrast to these findings, chronic inhibition of NO synthesis with L-NAME (3 weeks) in normal rats does not increase ET-1 levels or gene expression.36 Only a few reports are available on the NO-endothelin interaction in humans. Although nitrovasodilators can reduce ET-1 production by human endothelial cells in culture,37 infusion of nitroglycerin, an NO-donating drug, does not change plasma ET-1 levels in healthy subjects.11 In a recent study in healthy men, the NO synthase inhibitor NG-monomethyl-L-arginine temporarily (only after 20 minutes) increased ET-1 levels from 7.6 to 9.6 pmol/L.12 In the present study, however, we did not find a temporary increase in already elevated ET-1 concentration. One possible explanation is that the continuous high release of ET-1 during sepsis resulted in a depletion of storage vesicles with ET-1 (or its precursor).38 The results from the present study and previous reports suggest that increased production of ET-1 does not play a major role in the rise in blood pressure during prolonged inhibition of NO synthesis.
However, some reservations must be made regarding interpretation of plasma ET-1 levels. Plasma levels of ET-1 may not correctly reflect production rate, and the local concentration of the peptide at the vascular smooth muscle binding sites is probably more essential. For instance, big endothelin, which needs conversion to endothelin by tissue endothelin-converting enzyme to gain activity, is able to cause vasoconstriction without notable increases in plasma endothelin.39 Because the main ET-1 release seems to occur abluminally, local concentrations of ET-1 are probably higher than in the plasma.40 In the present study, therefore, increased local production of ET-1 may have occurred with L-NAME without detectable changes in plasma concentration. Similar reservations must be made regarding nitrite/nitrate levels. NO is but one of the ways that nitrite and nitrate are formed, and L-NAME infusion did not result in reduced serum levels of nitrite and nitrate, despite increased vasoconstriction. Possibly, plasma levels of nitrite and nitrate do not directly reflect the local amount of NO released, and active excretion of nitrite/nitrate through the kidneys and gastrointestinal tract may have influenced the plasma levels currently measured.41
Cortisol has a vital role in the maintenance of vascular tone and endothelial function.42 Furthermore, cortisol potentiates the vasoconstrictor actions of catecholamines.43 Thus, increases in plasma cortisol may indirectly increase vasopressor tone. Animal studies have shown that inhibition of NO synthesis with L-NAME stimulates adrenal steroidogenesis.44 45 We hypothesized that increased cortisol production might be an additional mechanism by which L-NAME increases blood pressure. However, we found no evidence of changes in cortisol levels during inhibition of NO synthesis in patients with septic shock. We conclude that changes in cortisol levels do not contribute to the increase in blood pressure with L-NAME.
In conclusion, inhibitors of NO synthesis may unmask a tonic pressor response of ET-1 in humans with septic shock. Prolonged inhibition of NO synthesis does not influence the plasma levels of ET-1. These results suggest that ET-1 maintains blood pressure in human sepsis and that plasma ET-1 concentration may determine the vasopressor response of NO synthase inhibitors in septic shock. These findings may provide further evidence of interaction between NO and ET-1 in pathological conditions of the cardiovascular system in which an imbalance between endothelium-derived vasodilator and vasoconstrictor substances disturbs the normal regulation of vascular tone.
|
Footnotes |
|---|
Reprint requests to Jurgen A.M. Avontuur, Department of Surgery, University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, Netherlands.
Guest Editor for this article was Oscar A. Carretero, MD, Henry Ford Hospital, Detroit, Mich.
Received January 28, 1998; revision received September 25, 1998; accepted October 5, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Lüscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation. 1993;87(suppl V):V36–V44.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.[Medline] [Order article via Infotrieve]
3. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852–854.[Medline] [Order article via Infotrieve]
4. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664–666.[Medline] [Order article via Infotrieve]
5. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142.[Medline] [Order article via Infotrieve]
6. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587–590.
7.
Lerman A, Sandok EK, Hildebrand FL Jr, Burnett JC Jr.
Inhibition of endothelium-derived relaxing factor
enhances endothelin-mediated vasoconstriction. Circulation. 1992;85:1894–1898.
8. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Löffler BM, Müller M, Neidhart W, Ramuz H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759–761.[Medline] [Order article via Infotrieve]
9.
Richard V, Hogie M, Clozel M, Löffler B,
Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone
after inhibition of nitric oxide synthesis in rats.
Circulation. 1995;91:771–775.
10.
Filep JG. Endogenous endothelin modulates
blood pressure, plasma volume, and albumin escape after
systemic nitric oxide blockade. Hypertension. 1997;30:22–28.
11. Thomson LL, Iversen HK, Emmeluth C, Bie P. Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects. Eur J Clin Pharmacol. 1995;48:139–142.[Medline] [Order article via Infotrieve]
12.
Ahlborg G, Lundberg JM. Nitric oxide-endothelin-1
interaction in humans. J Appl Physiol. 1997;82:1593–1600.
13. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:953–963.
14.
Avontuur JA, Bruining HA, Ince C. Nitric oxide causes
dysfunction of coronary autoregulation in endotoxemic rats.
Cardiovasc Res. 1997;35:368–376.
15. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, Peitzman AB. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg. 1991;214:621–626.[Medline] [Order article via Infotrieve]
16. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterisation of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990;101:746–752.[Medline] [Order article via Infotrieve]
17.
Meyer J, Traber LD, Nelson S, Nelson S, Lentz CW,
Nakazawa H, Herndon DN, Noda H, Traber DL. Reversal of hyperdynamic
responses to continuous endotoxin administration by inhibition of NO
synthesis. J Appl Physiol. 1992;73:324–328.
18.
Petros A, Lamb G, Leone A, Moncada S, Bennet D,
Vallance P. Effects of a nitric oxide synthase inhibitor in
humans with septic shock. Cardiovasc Res. 1994;28:34–39.
19. Kiehl MG, Ostermann H, Meyer J, Kienast J. Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock. Intensive Care Med. 1997;23:561–566.[Medline] [Order article via Infotrieve]
20. Avontuur JAM, Tutein Nolthenius RP, van Bodegom JW, Bruining HA. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med. 1998;26:660–667.[Medline] [Order article via Infotrieve]
21. Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock. 1991;33:222–227.[Medline] [Order article via Infotrieve]
22. Sanai L, Haynes WG, MacKenzie A, Grant IS, Webb DJ. Endothelin production in sepsis and the adult respiratory distress syndrome. Intensive Care Med. 1996;22:52–56.[Medline] [Order article via Infotrieve]
23. Bone RC, Fischer CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Crit Care Med. 1989;17:389–393.[Medline] [Order article via Infotrieve]
24. Smits P, Hofman H, Rosmalen F, Wollersheim T, Thien T. Endothelin-1 in patients with Raynaud's phenomenon. Lancet. 1991;337:236.[Medline] [Order article via Infotrieve]
25. Phizackerley PJ, Al-Dabbagh SA. The estimation of nitrate and nitrite in saliva and urine. Anal Biochem. 1983;131:242–245.[Medline] [Order article via Infotrieve]
26.
Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP,
Grobbee DE, de Jong FH, Lamberts SW. Interperson variability but
intraperson stability of baseline plasma cortisol concentrations, and
its relation to feedback sensitivity of the
hypothalamo-pituitary-adrenal axis to a low dose of
dexamethasone in elderly individuals. J Clin
Endocrinol Metab. 1998;83:47–54.
27. Ohta K, Hirata Y, Imai T, Kanno K, Emori T, Shichiri M, Marumo F. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun. 1990;169:578–584.[Medline] [Order article via Infotrieve]
28. Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol. 1997;15:163–167.[Medline] [Order article via Infotrieve]
29. Anggard E, Galton S, Rae G, Thomas R, McLoughin L, de Nucci G, Vane JR. The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol. 1989;13(suppl 5):S46–S49.
30. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1989;333:991–992.
31.
Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S,
D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes
to the vasodilation of septic shock. Circulation. 1997;95:1122–1125.
32.
Vierhapper H, Wagner O, Nowotny P, Waldhäusl W.
Effect of endothelin-1 in man. Circulation. 1990;81:1415–1418.
33.
Kaasjager KAH, Koomans HA, Rabelink TJ.
Endothelin-1–induced vasopressor responses in essential hypertension.
Hypertension. 1997;30:15–21.
34.
Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax
CC, Webb DJ. Systemic endothelin receptor blockade decreases
peripheral vascular resistance and blood pressure in
humans. Circulation. 1996;93:1860–1870.
35. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732–736.[Medline] [Order article via Infotrieve]
36.
Sventec P, Turgeon A, Schiffrin EL. Vascular
endothelin-1 gene expression and effect on blood pressure of chronic
ETA endothelin receptor antagonism after nitric
oxide synthase inhibition with L-NAME in normal rats.
Circulation. 1997;95:240–244.
37. Saijonmaa O, Risimäki A, Fyhrquist F. Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Commun. 1990;173:514–520.[Medline] [Order article via Infotrieve]
38.
Harrison VJ, Barnes K, Turner AJ, Wood E, Corder R,
Vane JR. Identification of endothelin-1 and big endothelin-1 in
secretory vesicles isolated from bovine aortic
endothelial cells. Proc Natl Acad Sci
U S A. 1995;92:6344–6348.
39. Teerlink JR, Carteaux JP, Löffler BM, Clozel M, Clozel JP. Big endothelin as a probe for the endothelin paracrine system: dissociation of plasma endothelin levels and hemodynamic effects. Circulation. 1993;88(suppl I):I-182. Abstract.
40.
Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S,
Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of
endothelin-1 by cultured endothelial cells.
J Biol Chem. 1992;267:16066–16068.
41.
Leaf CD, Wishnok JS, Hurley JP, Rosenblad D, Fox JG,
Tannenbaum SR. Nitrate biosynthesis in rats, ferrets and humans:
precursor studies with L-arginine.
Carcinogenesis. 1990;11:855–858.
42.
Lamberts SW, Bruining HA, de Jong FH.
Corticosteroid therapy in severe illness. N
Engl J Med. 1997;337:1285–1292.
43.
Kalsner S. Mechanism of hydrocortisone potentiation of
responses to epinephrine and norepinephrine in
rabbit aorta. Circ Res. 1969;24:383–395.
44. Adams ML, Nock B, Truong R, Cicero TJ. Nitric oxide control of steroidogenesis: endocrine effects of NG-nitro-L-arginine and comparisons to alcohol. Life Sci. 1991;50:35–40.
45. Giordano M, Vermeulen M, Trevani AS, Dran G, Andonegui G, Geffner JR. Nitric oxide synthase inhibitors enhance plasma levels of corticosterone and ACTH. Acta Physiol Scand. 1996;157:259–264.In this study, we tested whether ET-1 contributes to the vasopressor action of the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) in patients with severe septic shock. Continuous infusion of L-NAME 1 mg · kg-1 · h-1 IV for 12 hours increased blood pressure and systemic vascular resistance. Although no significant changes in the plasma concentration of ET-1 were found, the increase in blood pressure and systemic vascular resistance correlated positively with the level of ET-1. These findings may indicate that inhibitors of NO synthesis unmask a tonic pressor response of endothelin-1 in human septic shock.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. Papassotiriou, N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human Plasma Clin. Chem., June 1, 2006; 52(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Young The heart and circulation in severe sepsis Br. J. Anaesth., July 1, 2004; 93(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Aird The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome Blood, May 15, 2003; 101(10): 3765 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.J. HACKETT, A.P. J. THOMSON, and C.A. HART Cytokines, chemokines and other effector molecules involved in meningococcal disease J. Med. Microbiol., October 1, 2001; 50(10): 847 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamashita, S. Kawashima, Y. Ohashi, M. Ozaki, T. Ueyama, T. Ishida, N. Inoue, K.-i. Hirata, H. Akita, and M. Yokoyama Resistance to Endotoxin Shock in Transgenic Mice Overexpressing Endothelial Nitric Oxide Synthase Circulation, February 29, 2000; 101(8): 931 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Stoclet, M. C. Martinez, P. Ohlmann, S. Chasserot, C. Schott, A. L. Kleschyov, F. Schneider, and R. Andriantsitohaina Induction of Nitric Oxide Synthase and Dual Effects of Nitric Oxide and Cyclooxygenase Products in Regulation of Arterial Contraction in Human Septic Shock Circulation, July 13, 1999; 100(2): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||